Conformational Dynamics of Protein Tyrosine Kinases Src and Abl

蛋白酪氨酸激酶 Src 和 Abl 的构象动力学

• 批准号: 8197751
• 负责人: Markus A Seeliger
• 金额: $ 24.65万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-15 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8197751
• 关键词: Active Sites; Address; Affect; Affinity; Binding; Biochemical; Biological Assay; Catalysis; Cell Nucleus; Cell division; Chimeric Proteins; Chronic Myeloid Leukemia; Clinical; Complex; DDR1 gene; Data; Disease; Drug Delivery Systems; Drug resistance; Electrostatics; Elements; Energy Metabolism; Environment; Event; Gleevec; Goals; Imatinib; Kinetics; Ligand Binding; Manuscripts; Mediating; Methods; Molecular Conformation; Motion; Nuclear Magnetic Resonance; Pathway interactions; Patients; Pharmaceutical Preparations; Phosphotransferases; Process; Protein Dynamics; Protein Kinase; Proteins; Proto-Oncogenes; Publishing; Reaction; Regulation; Relaxation; Roentgen Rays; Role; Rotation; Signal Transduction; Specificity; Staging; Structure; Therapeutic; Vertebral column; X-Ray Crystallography; base; conformational conversion; design; flexibility; inhibitor/antagonist; inorganic phosphate; insight; kinase inhibitor; research study; resistance mutation; scaffold; src-Family Kinases; success; tool

Protein kinases mediate many cell signaling events, and their tight control is essential for regulating vital processes ranging from cell division to energy metabolism. Thus, it is not surprising that protein kinases are directly or indirectly involved in many diseases and that kinases are key drug targets. For example, Src kinase was the first identified proto-oncogene and the formation of a de-regulated Abl fusion protein (BCRAbI) is the cause of disease in 95% of patients with chronic myeloid leukemia. X-ray crystal structures have shown that the same kinases can attain an active and various inactive conformations, implying that kinases are inherently flexible. How the active and inactive states are stabilized and how these states interconvert are key questions in understanding kinase regulation. Because X-ray crystal structures provide only static snapshots, we will use nuclear magnetic resonance (NMR) experiments and ligand binding kinetics to study the timescales and amplitudes of structural interconversions in Abl and Src kinase domains. BCR-AbI is the target of the clinically highly successful drug imatinib (Gleevec¿, Novartis) in the treatment of chronic myelogenous leukemia (CML). The clinical success of imatinib is due to its excellent specificity, binding only to the inactive conformation of the kinase. Therefore drug binding is intimately related to the interconversion between active and inactive states. The goal of this study is to examine timescales and pathways ofthese interconversions between active and inactive conformations, how dynamics of structural elements relate to catalytic turnover of the kinase and how drug resistance mutations affect these dynamics. Therefore, we will compare the timescales and amplitudes of backbone motions between Src and Abl kinases in the presence of drugs by NMR experiments. Ligand binding kinetics will be used to address the role of the regulatory domains on kinase dynamics and the binding mechanisms of different classes of kinase inhibitors. The role of protein plasticity and dynamics on inhibitor promiscuity will be addressed by structural studies on kinase*inhibitor complexes, inhibitor binding kinetics and biochemical assays.

蛋白激酶介导许多细胞信号转导事件，它们的严格控制对于调节重要的细胞信号至关重要。 从细胞分裂到能量代谢的过程。因此，蛋白激酶被认为是不足为奇的。 直接或间接参与许多疾病，激酶是关键的药物靶点。例如，源代码 激酶是第一个被鉴定的原癌基因，并且形成了失调的 Abl 融合蛋白 (BCRAbI) 是 95% 慢性粒细胞白血病患者的致病原因。 X射线晶体结构 已经表明，相同的激酶可以获得活性和各种非活性构象，这意味着 激酶本质上是灵活的。活动和非活动状态如何稳定以及这些状态如何稳定 相互转换是理解激酶调节的关键问题。因为 X 射线晶体结构提供 仅静态快照，我们将使用核磁共振（NMR）实验和配体结合 动力学来研究 Abl 和 Src 激酶结构域中结构互变的时间尺度和幅度。 BCR-AbI 是临床上非常成功的药物伊马替尼（格列卫，诺华）的靶点，用于治疗 慢性粒细胞白血病（CML）。伊马替尼的临床成功得益于其优异的特异性， 仅与激酶的非活性构象结合。因此，药物结合与 活动状态和非活动状态之间的相互转换。本研究的目的是检查时间尺度和 这些活性和非活性构象之间相互转化的途径，结构的动力学如何 这些元素与激酶的催化周转以及耐药突变如何影响这些动态有关。 因此，我们将比较 Src 和 Abl 之间骨干运动的时间尺度和幅度 通过 NMR 实验检测药物存在下的激酶。配体结合动力学将用于解决 调节域对激酶动力学的作用以及不同类别的结合机制 激酶抑制剂。蛋白质可塑性和动力学对抑制剂混杂的作用将通过 激酶*抑制剂复合物、抑制剂结合动力学和生化测定的结构研究。

项目成果

How does a drug molecule find its target binding site?

• DOI: 10.1021/ja202726y
• 发表时间: 2011-06-22
• 期刊: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
• 影响因子: 15
• 作者: Shan, Yibing;Kim, Eric T.;Eastwood, Michael P.;Dror, Ron O.;Seeliger, Markus A.;Shaw, David E.
• 通讯作者: Shaw, David E.